Sign in
SuspendedPhase 3

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

Key facts

Who runs it
Materia Medica Holding
Where
Russia20 sites in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
Phase
Phase 3
People taking part
314 people, planned
Started
12 Dec 2019
Ended
Dec 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • MMH-407
  • Placebo
Record updated
18 August 2023
Why it stopped
Due to the end of the ARVI and influenza season, it was suspended until approximately October 01, 2023

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Patients of male and female gender aged 18 to 64 years
  • Uncomplicated, moderate influenza supported by all the symptoms:; axillary temperature ≥38.1°С on physician examination; at least one moderate general symptom of influenza infection (headache, fever/chill, aches in the muscles/joints, weakness/drowsiness); at least one moderate respiratory symptom of influenza infection (cough, sore throat, or nasal congestion)
  • Positive influenza rapid test (detection of virus antigens in the nasal epithelium)
  • First 24 hours of the onset of illness
  • Patients who agree to use a reliable method of birth control during the study
  • Patients who have provided signed Participant Information Sheet and Informed Consent form to participate in a clinical trial

Who cannot take part

  • Prior history or diagnosis of primary or secondary immunodeficiency
  • Pregnancy, breast-feeding, childbirth within less than 3 months prior to the inclusion in the trial, or unwillingness to use contraceptive methods during the study
  • Prior history of non-adherence to medication; mental disorder; or alcohol or substance abuse, which, in the investigator's opinion, will compromise compliance with study procedures
  • Use of any of the "Prohibited Concomitant Medications" within 2 weeks prior to study entry
  • Participation in other clinical studies within 3 months prior to the inclusion in this study
  • Severe influenza infection that requires hospitalization
  • Suspected pneumonia or bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) that requires the use of antibiotics, starting from the first day of illness
  • Suspected early manifestations of a condition that, on its first onset, produces symptoms similar to those of influenza (other infectious diseases and/or influenza-like syndrome associated with the first onset of a systemic connective tissue disorder or another condition)
  • Patients with any known or suspected malignant neoplasm
  • An exacerbated or decompensated chronic disease interfering with the subject's participation in the clinical trial
  • Malabsorption syndrome, including congenital or acquired lactase deficiency (or any other disaccharidase deficiency), and/or galactosemia
  • Current allergy to or intolerance of the active substances or any of the excipients in the medications used in the treatment
  • Patients who require the use of antivirals that are not permitted during the study
  • Current season influenza vaccination
  • Patients who, as judged by the investigator, will fail or be unwilling to comply with the observation requirements or adhere to the dosing regimen during the study
  • Patients who are related to any of the on-site research personnel directly involved in the conduct of the study or are an immediate relative of the investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted)
  • Patients who work for OOO "NPF "Materia Medica Holding" (i.e. company employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The main purpose of this study is:

Read full original descriptionShow less

• to evaluate the efficacy and safety of MMH-407 in the treatment of influenza in outpatient adults.

The 2 groups in the trial

  • MMH-407Treatment being tested

    Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.

  • PlaceboPlacebo, for comparison

    Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Placebo-controlled, Double-blind, Randomized Clinical Trial in Parallel Groups to Evaluate the Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults
Record updated
18 August 2023